Exploring industries that can serve as pillars outside automotive
First written in FY2023. 5 of 14 entries say "Advanced", first in FY2024-Q3. Latest entry: FY2026.
The whole theme swung hardest in 2021: 2 of 9 companies on the "Worse" side.
0 other companies' latest entry also says "Reframed".
- FY2026ReframedAnnual report
「In the Other business, the Company will dissolve its bio business and concentrate management resources on the reliability evaluation and precision machining businesses. Going forward, it will pursue expansion through new businesses, technologies, business alliances and M&A.」
The policy for developing a pillar outside the automotive business has shifted from expanding the bio business to dissolving the bio business and concentrating on reliability evaluation and precision machining, with further expansion through new businesses, technologies, alliances and M&A. - FY2026-H1Declining bio-business revenueAnnual report
「In the Other Business, revenue in the bio business declined because reliability testing of medical consumables under a Ministry of Health, Labour and Welfare project was completed. As a result, revenue was ¥11,437 thousand, down 56.7% year on year, and operating loss was ¥9,873 thousand, compared with an operating loss of ¥11,221 thousand in the previous fiscal year.」
In the bio business, positioned as a non-automotive business area, revenue fell 56.7% year on year after reliability testing of medical consumables under a Ministry of Health, Labour and Welfare project was completed. No change to the policy of expanding non-automotive fields is stated. - FY2025AdvancedAnnual report
「In the fiscal year ending June 2025, we reduced our dependence on specific customers to some extent through sales expansion in the semiconductor industry in power-cycle testing, cross-sectional polishing, analysis and evaluation, and through prototype orders in the healthcare industry in the micromachining business.」
Expanded sales to the semiconductor industry and prototype orders in healthcare demonstrate concrete progress in reducing dependence on automotive customers and specific customers. - FY2025-H1AdvancedAnnual report
「In the Other Business, revenue increased substantially in the bio business because orders for contract testing remained strong.」
Contract testing orders were strong in the bio business, which had been positioned as a non-automotive pillar, and revenue in the Other Business increased 31.4% year on year. - FY2024AdvancedAnnual report
「Going forward, we will work to reduce the proportion of sales from specific customers by expanding horizontally in power-cycle testing, cross-sectional polishing, analysis and evaluation within this business, and by expanding the business through entry into the healthcare field in the micromachining business.」
The company explicitly identifies horizontal expansion in reliability assessment and entry into healthcare as measures to reduce dependence on specific customers. Sales to DENSO CORPORATION declined from 20.9% to 17.4%. - FY2024-Q3AdvancedAnnual report
「Meanwhile, orders for contract testing in the medical field are increasing.」
Orders for contract testing in the medical field, identified as a potential pillar outside automotive, are increasing. - FY2023First statedAnnual report
「Going forward, we will develop industries that can serve as pillars outside the automotive industry by entering the healthcare field in the micromachining business and expanding the bio business, which we are pursuing as a new business.」
The company identifies expansion into non-automotive fields, including healthcare and bio-related services, as a priority in response to concentration in major customers and industries.